All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-02-01T15:14:20.000Z

How does the EBMT support the development of CAR T therapies?

Feb 1, 2020
Share:

Bookmark this article

During the 2nd European CAR T Cell Meeting in Sitges, ES, the Lymphoma Hub was delighted to speak to Nicolaus Kröger, University Hospital Hamburg, Hamburg, DE. We asked: How does the EBMT support the development of CAR T therapies?

Nicolaus Kröger explains that the EBMT is highly committed to the development of CAR T cells. He tells us that EBMT has received a positive opinion by the European Medicines Agency thus the EBMT is open to register all CAR T cells around Europe. He also discusses the new registry that was established by the EBMT with CIBMTR to collect CAR T data. Lastly, he talks about the development of the CAR T cell governance structure, where all stakeholders form a group with the shared aim to develop CAR T cells in Europe.

How does the EBMT support the development of CAR T therapies?

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox